Increased Use of Off-label Antipsychotic Drugs in Children

September 12, 2012 — A national study conducted by researchers at The Children’s Hospital of Philadelphia (CHOP) shows increased use of powerful antipsychotic drugs to treat publicly insured children over the past decade. The study, published today in the journal Health Services Research, found a 62 percent increase in the number of Medicaid-enrolled children ages 3 to 18 taking antipsychotics, reaching a total of 354,000 children by 2007.

Increased use of antipsychotic drugs in children seen across a wide range of mental health diagnoses

Increased antipsychotic use was observed across a wide range of mental health diagnoses, and was particularly high for children with ADHD or conduct disorder, although the FDA has not approved the drugs to treat these conditions in children. In total, 65 percent of children prescribed antipsychotics in 2007 were using the drugs “off-label,” or without FDA safety and efficacy data to support their use to treat young patients.

The CHOP study is the second released this month that focuses on the use of antipsychotic drug use in children and is largest of its kind, representing 35 percent of children in the country.

Antipsychotic drug use in children a pediatric research priority for National Institutes of Health

“Given the significant proportion of off-label use of antipsychotics in children, it is reassuring that these drugs have been recognized as a priority for pediatric research by the National Institutes of Health,” said David M. Rubin, MD, MSCE, a senior author of the study, attending pediatrician, and co-director of CHOP’s PolicyLab. “If a child is prescribed an antipsychotic, it’s important for doctors to inform parents and caregivers if the drug is being prescribed off-label, of potential side effects, and of counseling therapies that might be offered as an alternative to medication.”

The frequent off-label use of antipsychotics has raised concern among many healthcare providers, especially in light of evidence linking antipsychotics with an increased risk of serious metabolic side effects in children, including weight gain and diabetes.

Increase in use partly due to increase in mental health diagnoses in children

The researchers note that the increase in antipsychotic use is due to in part to an overall increase in the number of mental health diagnoses assigned to children. Researchers found a 28 percent increase in the number of children with a mental health diagnosis, but this alone did not account for the spike in prescriptions.

“We knew that the number of children prescribed antipsychotics had grown steadily over the past two decades, particularly among children with public insurance,” said Meredith Matone, MHS, the study’s lead author and a researcher at PolicyLab. “With this study, we wanted to learn more about why these drugs are being used so often, what diagnoses they’re being used to treat, and how prescribing patterns changed over the course of the last decade.”

While schizophrenia, bipolar disorder and autism were the most likely diagnoses to result in an antipsychotic prescription, children with these disorders did not make up the majority of antipsychotic users. Children with ADHD and those who were diagnosed with three or more concurrent mental health disorders made up the largest group of children taking antipsychotics. In 2007, 50 percent of children taking antipsychotics had a diagnosis of ADHD, and 14 percent had ADHD as their only diagnosis.

“The fact that we see an uptick in prescribing antipsychotics for many diagnoses tells us that antipsychotics are likely being used to treat specific behaviors, like aggression, that are shared among a variety of mental health diagnoses,” explained Matone. “Insights like this are only available by conducting very large-scale studies like this one. Reaching an average of 15 million children a year provided the needed national perspective on medication use. Continuing to conduct population-based, public health studies is crucial to inform policies and guidelines for the use of antipsychotics for children.”

More information

For more information about the study and on PolicyLab’s body of child welfare work, visit the PolicyLab website.

About PolicyLab at The Children’s Hospital of Philadelphia

PolicyLab develops evidence-based solutions for the most challenging health-related issues affecting children. PolicyLab engages in research that is both responsive to community needs and relevant to policy priorities, partnering with practitioners, policymakers, and families throughout the research process. Through its work, PolicyLab identifies the programs, practices, and policies that support the best outcomes for children and their families, disseminating its findings beyond research and academic communities as part of its commitment to transform evidence to action.

Contact

Dana Mortensen, Children's Hospital of Philadelphia, 267-426-6092 or mortensen@email.chop.edu